Blog

Gerry Hanna: ESMO-ESTRO Framework for Radiotherapy and Systemic Therapy Safety

Gerry Hanna/X

Jun 14, 2025, 03:27

Gerry Hanna: ESMO-ESTRO Framework for Radiotherapy and Systemic Therapy Safety

Gerry Hanna, Marie Curie Chair of Clinical Oncology at Trinity College Dublin, posted on X:

“In this month’s Radiotherapy and Oncology Journal Van Aken, et al describe a framework to assess interactions and safety of targeted therapies or Immunotherapy combinations with Radiotherapy.

Pragmatic and biologically informed guidance on how to address.”

Title: ESMO-ESTRO framework for assessing the interactions and safety of combining radiotherapy with targeted cancer therapies or immunotherapy

Authors: Evert S.M. van Aken, Bharti Devnani, Luis Castelo-Branco, Dirk De Ruysscher, Diogo Martins-Branco, Corrie A.M. Marijnen, Barbara Muoio, Claus Belka, Florian Lordick, Stephanie Kroeze, George Pentheroudakis, Dario Trapani, Umberto Ricardi, Ajeet Kumar Gandhi, Arsela Prelaj, Sean M. O’Cathail, Monique C. de Jong

Read The Full Article at Radiotherapy and Oncology Journal.

Gerry Hanna: ESMO-ESTRO Framework for Radiotherapy and Systemic Therapy Safety

More posts featuring Gerry Hanna.

Ajeet Kumar Gandhi Arsela Prelaj Barbara Muoio Bharti Devnani Claus Belka Corrie A.M. Marijnen Dario Trapani Diogo Martins Branco Dirk de Ruysscher Florian Lordick George Pentheroudakis Gerry Hanna immunotherapy Luis Castelo-Branco Monique C. de Jong radiotherapy Radiotherapy and Oncology Journal Sean M. O’Cathail Stephanie Kroeze Umberto Ricardi Van Aken

MiNK Therapeutics Stock Surges on Breakthrough Testicular Cancer Remission and iNKT Cell Therapy Progress

Tabelecleucel (Ebvallo) FDA Update: Approval Delayed Despite Positive Phase 3 Data

New Paper Alert: Breakthrough iNKT Cell Therapy Achieves Complete Remission in Metastatic Germ Cell Tumor

"God Invented This" - Pat Soon-Shiong on Cancer Discovery

Kevin Conroy: Oncodetect is Now Covered by Medicare in Stage IV Colorectal Cancer